Transarterial Chemoembolization with Additional Cisplatin Infusion for Hepatocellular Carcinoma Invading the Hepatic Vein

Kim, Hyo Cheol; Lee, Jeong Hoon; Chung, Jin Wook; Kang, Beomsik; Yoon, Jung Hwan; Kim, Yoon Jun; Lee, Hyo Suk; Jae, Hwan Jun; Park, Jae Hyung

doi:10.1016/j.jvir.2012.11.002

Cited by 46 publications

(38 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our study may have yielded a better survival rate owing to the fact that previous research defined major vascular invasion contains involving the IVC (20) or PVTT (5,10,18). Our study reported that TACE led to an overall survival rate of 15.6% at 3 years, and 9.1 months of median survival, similar to previous findings (12,13). The patients with HVTT in the HR group achieved a better prognosis than the patients in the TACE group, as in previous similar studies on PVTT (26) or the IVC/RA (21) (P = 0.015).…”

Section: Discussionsupporting

confidence: 89%

See 1 more Smart Citation

Hepatic resection versus transcatheter arterial chemoembolization for the treatment of hepatocellular carcinoma with hepatic vein tumor thrombus

Zhang

Wei

Guo

et al. 2015

Jpn. J. Clin. Oncol.

View full text Add to dashboard Cite

Objective: To compare the outcomes of hepatic resection and transcatheter arterial chemoembolization for resectable hepatocellular carcinoma with hepatic vein tumor thrombus. Methods: From January 2006 to November 2013, 28 patients initially diagnosed with resectable hepatocellular carcinoma combined with hepatic vein tumor thrombus received hepatic resection. These patients were compared with 56 case-matched controls (1:2 ratio) selected from a pool of 91 patients who received transcatheter arterial chemoembolization as an initial treatment during the same period. Clinical characteristics, adverse events, overall survival and survival-related factors were analyzed. Results: The 1-, 2-and 3-year overall survival rates were 66.5, 37.4 and 28.5% for the hepatic resection group and 32.3, 18.7 and 15.6% for the transcatheter arterial chemoembolization group (P = 0.015), respectively. No significant difference was found between the two groups in terms of complications and mortality. Multivariate analyses revealed combined portal vein tumor thrombosis (HR = 2.116; 95% CI: 1.26-3.57; P = 0.005) and treatment allocation (hepatic resection = 2.289; 95% CI, 1.30-4.02; P = 0.004) as risk factors for overall survival. Conclusions: Hepatic resection provides a good prognosis for hepatocellular carcinoma patients with hepatic vein tumor thrombus compared with patients undergoing transcatheter arterial chemoembolization, and the most important factor related to survival was co-existence with portal vein invasion.

show abstract

Section: Discussionsupporting

confidence: 89%

“…The incidence of HVTT (2.5%) in our study was similar to the incidences previously reported ranging from 1.4-4.9% (5,12,14,25,30). Owing to the relatively low incidence of HVTT compared with PVTT, little is known about HVTT (14).…”

Section: Discussionsupporting

confidence: 88%

Hepatic resection versus transcatheter arterial chemoembolization for the treatment of hepatocellular carcinoma with hepatic vein tumor thrombus

Zhang

Wei

Guo

et al. 2015

Jpn. J. Clin. Oncol.

View full text Add to dashboard Cite

show abstract

“…Details of the procedure performed in our institution have been described previously [16]. Briefly, a solution that contained 10–60 mg of doxorubicin hydrochloride emulsion (Adriamycin RDF; Ildong Pharmaceutical, Seoul, Korea) and 2–12 mL of ethiodized oil (Lipiodol; Andre Guerbet, Aulnay-sous-Bois, France) was infused through a microcatheter (Microferret; Cook, Bloomington, IN, or Progreat; Terumo, Tokyo, Japan) until arterial flow stasis was achieved and/or ethiodized oil appeared in the portal branches.…”

Section: Methodsmentioning

confidence: 99%

Serum Insulin-Like Growth Factor-1 Predicts Disease Progression and Survival in Patients with Hepatocellular Carcinoma Who Undergo Transarterial Chemoembolization

et al. 2014

Self Cite

View full text Add to dashboard Cite

Insulin like-growth factor-1 (IGF-1) reflects hepatic synthetic function and plays a major role in the development and progression of various cancers. In the present study, we investigated whether baseline serum IGF-1 levels predict time-to-progression (TTP) and overall survival (OS) in hepatocellular carcinoma (HCC) patients treated with transarterial chemoembolization (TACE). A total of 155 consecutive treatment-naive patients with HCC who had undergone TACE as initial treatment were included from a prospective cohort. Baseline serum IGF-1 levels were analyzed with regard to their associations with disease progression and survival. During a median follow-up period of 41.8 months, patients with low IGF-1 levels showed significantly shorter TTP (median, 6.0 months; 95% confidence interval [CI], 4.5–7.6) than patients with high IGF-1 levels (median, 16.5 months; 95% CI, 4.9–28.1; p = 0.003). In the multivariate analysis, BCLC stage, serum vascular endothelial growth factorlevels, and IGF-1 levels were independent risk factors for disease progression. The hazard ratio (HR) of progression for each 10 ng/mL decrease in IGF-1 level was 1.072 (95% CI, 1.029–1.117; p = 0.001). Furthermore, together with tumor size, stage, and treatment response, IGF-1 levels were an independent predictor of poorer survival (for each 10 ng/mL decrease in IGF-1 level; HR, 1.057; 95% CI, 1.001–1.115; p = 0.045). In conclusion, low baseline IGF-1 levels independently correlated with shorter TTP and poorer OS in patients with HCC who underwent TACE.

show abstract

“…Studies have shown that the efficacy of lobaplatin-TACE is higher than the conventional TACE or transcatheter arterial embolization (Zhou et al, 2010;Shi et al, 2013). Our results showed that the mean survival time in TACE group was 19.5 months, higher than that in the literatures (Ho and Yang, 1992;Zhao et al, 2010;Kim et al, 2013). We believed that it may owe to lobaplatin.…”

Section: Discussionmentioning

confidence: 43%

Lobaplatin-TACE Combined with Radioactive¹²⁵I Seed Implantation for Treatment of Primary Hepatocellular Carcinoma

Peng¹,

Yang²,

Zhang³

et al. 2014

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

Asian Pac J Cancer Prev, 15 (13), [5155][5156][5157][5158][5159][5160] IntroductionPrimary hepatocellular carcinoma (HCC), with a climbing incidence year by year, is one of the most common malignant tumors and presents a spreading trend worldwide (Sherman, 2010). Current principal means for the treatment of HCC include surgical treatment (liver resection and liver transplantation), regional treatment (transcatheter arterial chemoembolization (TACE) and topical therapy (ablation therapy, etc.) (Bruix and Sherman, 2011;Forner et al., 2012;Shi et al., 2013). However, when the patients refer to the hospital, most of them have been at the latest stage and consequently few of them can undergo surgical treatment. Moreover, the recurrence rate of HCC is high. Its 5-year recurrence rate can be up to 80%, while less than 20% of the recurrent HCC can get a re-resection (Bruix and Sherman, 2011). Liver transplantation can be a favorable approach for the treatment of liver cancer in the final stage, but the donors are very scarce and the cost is huge. Ultimately, most of the patients have to receive regional or topical treatment. I seed implantation (TACE+ 125I group). After treatment, the local remission rates and postoperative complications of two groups were compared using the Pearson Chi-square test. Overall survival in the two groups was calculated using Kaplan-Meier survival curves and the differences were tested using Log-rank test. Results: There were 7 cases of complete response (CR), 13 of partial response (PR), 6 of stable disease (SD) and 17 of progressive disease (PD) in the TACE group, with 13 cases of CR, 9 of PR, 5 of SD and 5 of PD in the TACE+ 125

show abstract

Transarterial Chemoembolization with Additional Cisplatin Infusion for Hepatocellular Carcinoma Invading the Hepatic Vein

Cited by 46 publications

References 26 publications

Hepatic resection versus transcatheter arterial chemoembolization for the treatment of hepatocellular carcinoma with hepatic vein tumor thrombus

Hepatic resection versus transcatheter arterial chemoembolization for the treatment of hepatocellular carcinoma with hepatic vein tumor thrombus

Serum Insulin-Like Growth Factor-1 Predicts Disease Progression and Survival in Patients with Hepatocellular Carcinoma Who Undergo Transarterial Chemoembolization

Lobaplatin-TACE Combined with Radioactive¹²⁵I Seed Implantation for Treatment of Primary Hepatocellular Carcinoma

Contact Info

Product

Resources

About

Transarterial Chemoembolization with Additional Cisplatin Infusion for Hepatocellular Carcinoma Invading the Hepatic Vein

Cited by 46 publications

References 26 publications

Hepatic resection versus transcatheter arterial chemoembolization for the treatment of hepatocellular carcinoma with hepatic vein tumor thrombus

Hepatic resection versus transcatheter arterial chemoembolization for the treatment of hepatocellular carcinoma with hepatic vein tumor thrombus

Serum Insulin-Like Growth Factor-1 Predicts Disease Progression and Survival in Patients with Hepatocellular Carcinoma Who Undergo Transarterial Chemoembolization

Lobaplatin-TACE Combined with Radioactive125I Seed Implantation for Treatment of Primary Hepatocellular Carcinoma

Contact Info

Product

Resources

About

Lobaplatin-TACE Combined with Radioactive¹²⁵I Seed Implantation for Treatment of Primary Hepatocellular Carcinoma